Assessing Protein Immunogenicity with a Dendritic Cell Line-Derived Endolysosomal Degradome by Egger, Matthias et al.
Assessing Protein Immunogenicity with a Dendritic Cell
Line-Derived Endolysosomal Degradome
Matthias Egger
1*, Alexander Ju ¨rets
2, Michael Wallner
1, Peter Briza
2, Silke Ruzek
3, Stefan Hainzl
4, Ulrike
Pichler
2, Claudia Kitzmu ¨ller
5, Barbara Bohle
5, Christian G. Huber
3,F a ´tima Ferreira
1
1Christian Doppler Laboratory for Allergy Diagnosis and Therapy, Department of Molecular Biology, University of Salzburg, Salzburg, Austria, 2Department of Molecular
Biology, Division of Allergy and Immunology, University of Salzburg, Salzburg, Austria, 3Department of Molecular Biology, Division of Chemistry and Bioanalytics,
University of Salzburg, Salzburg, Austria, 4Laboratory for Immunological and Molecular Cancer Research, Paracelsus Private Medical University of Salzburg, Salzburg,
Austria, 5Christian Doppler Laboratory for Immunomodulation, Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria
Abstract
Background: The growing number of novel candidate molecules for the treatment of allergic diseases imposed a dramatic
increase in the demand for animal experiments to select immunogenic vaccines, a pre-requisite for efficacy. Because no in
vitro methods to predict the immunogenicity of a protein are currently available, we developed an in vitro assay that
exploits the link between a protein’s immunogenicity and its susceptibility to endolysosomal proteolysis.
Methodology: We compared protein composition and proteolytic activity of endolysosomal fractions isolated from
murine bone marrow- and human blood- derived dendritic cells, and from the dendritic cell line JAWS II. Three
groups of structurally related antigen variants differing in their ability to elicit immune responses in vivo (Bet v
1.0101 and Bet v 1.0401, RNases A and S, holo- and apo-HRP) were subjected to in vitro simulated endolysosomal
degradation. Kinetics and patterns of generated proteolytic peptides were evaluated by gel electrophoresis and mass
spectrometry.
Results: Antigens displaying weak capacity of T cell priming in vivo were highly susceptible to endolysosomal proteases in
vitro. As proteolytic composition, activity, and specificity of endolysosomal fractions derived from human and murine
dendritic cells were comparable, the JAWS II cell line could be used as a substitute for freshly isolated human or murine cells
in in vitro degradation assays.
Conclusions: Endolysosomal fractions prepared from the JAWS II cell line provide a reliable tool for in vitro estimation of
protein immunogenicity. The rapid and simple assay described here is very useful to study the immunogenic properties of a
protein, and can help to replace, reduce, and refine animal experiments in allergy research and vaccine development in
general.
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Introduction
The development of a novel vaccine is a highly complex and
demanding process that, from the initial concept to a licensed
product, can take up to decades. Once a candidate has evolved in the
laboratory, it undergoes vast series of pre-clinical in vitro and in vivo
examination and optimization procedures. Evidently, only a minority
of candidates passes all these obstacles, is permitted to clinical trials,
accepted by regulatory agencies, and converted into a commercial
product. The development of allergy vaccines faces additional
problems, because unlike prophylactic vaccination, allergen-specific
immunotherapy (SIT) attempts to counteract an already established
pathological immune response [1]. Severe anaphylactic side effects
can result from interactions between the administered vaccine and
allergen-specific IgE antibodies of the atopic patient. Moreover, the
current use of extracts of undefined contents can lead to sensitizations
against new allergens during conventional immunotherapy [2]. Thus,
allergy research today focuses on strategies to improve both, safety
and clinical efficacy of SIT.
Others and we have proposed the substitution of allergen
extracts in immunotherapy by molecule-based vaccines in order to
implement safer and patient-tailored treatment [2,3]. However, in
contrast to infectious disease antigens, many allergens have been
reported to be weak immunogens [4–7], a property hampering
therapeutic success. Notably, it has been shown that allergen
isoforms can differ by both immunogenicity (T cell reactivity) and
allergenicity (IgE reactivity). For example, the birch pollen major
allergen Bet v 1 isoform 0401 activates T cells much more
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(hypoallergen) [4,9,10]. As molecules with such properties would
bypass IgE mediated side effects during SIT, they are considered
ideal allergy vaccines. Besides naturally occurring hypoallergens,
modern DNA technology facilitates genetic engineering of
recombinant hypoallergens [1–3,11,12]. However, the structural
manipulation required for hypoallergen generation [11] and the
production procedures [13] can severely affect the immunogenic-
ity of a recombinant protein [14–17]. For example, although
differing only by a single amino acid, one out of two in silico
designed recombinant Bet v 1 mutants with reduced IgE reactivity
lost its immunogenicity in mice [18]. Moreover, from 400 chimera
generated by DNA shuffling of 14 major tree pollen allergens, only
2 fulfilled the requirements for efficient vaccine candidates [19].
The screening of such large candidate libraries requires high-
throughput methods. Although IgE reactivity can be easily
evaluated by antibody-based in vitro experiments in microtiter
format, such tests are lacking for immunogenicity assessment. The
prediction of T cell reactivity (immunogenicity) is costly, time-
consuming, can only be performed for a limited number of
molecules, and depends on in vivo or cell-based ex vivo systems.
Nevertheless, ever since the first purified recombinant allergen was
available in the early 1990s [20], a multitude of proteins has been
produced as candidates for SIT [3,11,12]. Hence, the fast
development of new molecule-based allergy vaccines dramatically
increases the demand for animal sacrifice, conflicting the 3Rs
declaration of the European Partnership for Alternative Ap-
proaches to Animal Testing (EPAA).
Within the present study we established a degradation assay
based on earlier studies showing that susceptibility to endolysosomal
proteolysis by antigen presenting cells (APC) serves as in vitro marker
for protein immunogenicity [15,16]. This assay enables the pre-
selection of molecules with highest immunogenicity out of a big
repertoire of related candidate proteins, hence aiming to replace,
reduce, and refine animal experiments in allergy vaccine develop-
ment. Whereas previous work solely focused on the kinetics of
endolysosomal protein decomposition, we also evaluated the in vitro
generated antigen-derived peptides and performed comparative
fingerprinting of microsomal proteases. Moreover, we compared
the degradative potential of different types of human and murine
DC’s microsomes. In addition to previously investigated antigens
(i.e. ribonucleases A and S, as well as holo- and apo-horseradish
peroxidase) [15,16], we included two well-described allergens, i.e.
the high and low allergenic isoforms of the birch pollen major
allergen Bet v 1.0101 and Bet v 1.0401 [8], to evaluate the general
applicability of the assay. As source for the endolysosomal
hydrolases we employed a commercially available murine dendritic
cell (DC) line [21]. This approach enables high-throughput
screening for immunogenic candidates in vaccine development
saving time, costs, human blood donors, and animal sacrifice, and
might be interesting for any study on protein immunogenicity.
Methods
Subjects
All blood-donors gave written consent before enrollment in this
study, which was approved by the local Medical Ethical
Committee of Vienna.
Mice
BALB/c mice were obtained from Charles River Laboratories
(Wilmington, MA). All animal experiments were conducted
according to National guidelines approved by the Austrian
Ministry of Science (BMWF-66.012/0011-II/10b/2010).
Antigens
Recombinant Bet v 1.0101 (SwissProt accession: P15497) and
Bet v 1.0401 (SwissProt accession: P43177) were produced in
Escherichia coli as recently published [8]. Ribonuclease (RNase A
(SwissProt accession: P61823), RNase S, and holo-HRP (SwissProt
accession: P00433) were purchased from Sigma-Aldrich, St. Louis,
MO. Apo-HRP was prepared according to previously described
protocols [15].
Generation and culture of Dendritic Cells
Human mDCs (monocyte-derived DCs) obtained from hepa-
rinized blood samples and murine BMDCs (bone marrow-derived
DCs) were generated and cultured as described elsewhere [8,22].
The DC line JAWS II that has been established from bone
marrow cells of a p53 knockout C57BL/6 mouse, was purchased
from American Type Culture Collection (Manassas, VA) and
cultured as previously described [21].
Subcellular Fractionation and Fingerprinting of
Microsomes
Endosomes and lysosomes were isolated from DCs by differential
centrifugation [16]. Briefly, cells (10
7 cells/protein) were homoge-
nized in 10 mmol L
21 Tris/acetate pH 7 containing 250 mmol
L
21 sucrose using a Dounce tissue grinder (Sigma-Aldrich, St.
Louis,MO)and centrifugedfor10minutesat6,0006g.Toobtaina
total microsomal fraction, postnuclear supernatants were ultracen-
trifuged (60 minutes at 100,0006 g). Microsomal content was
released by 5 freeze-thaw cycles on liquid nitrogen and room
temperature respectively, and stored at 220uC. For microsome
fingerprinting 100 ng of microsomal proteins were reduced,
alkylated, and trypsinized using the CalbiochemH ProteoExtractH
All-in-One Trypsin digestion kit (EMD, Gibbstown, NJ) before
injection into a one-dimensional capillary HPLC system (Model
U3000, Dionex Benelux, Amsterdam, The Netherlands), equipped
with a low-pressure gradient micro-pump, a micro-autoinjector and
a capillary PS-DVB monolithic separation column (15060.2 mm
id).A 300 mingradient of 0–40%ACNin0.05% aqueous TFAwas
applied using a flow rate of 1 ml min
21. The chromatographic setup
was coupled to an ESI-LTQ Orbitrap mass analyzer (Thermo
Fisher Scientific GmbH, Bremen, Germany). Each sample was
analyzed in triplicate, while the peptides identified in one run were
excluded from data dependent decisions in the following runs by the
use of exclusion lists. Spectra were generated in positive mode in a
mass range of m/z 500–2000. Fragmentation of a maximum of
three precursors was realized in the ion trap using collision-induced
dissociation. The Mascot search engine (Matrix Science, London,
UK) and the software Proteome Discoverer (Thermo Fisher
Scientific GmbH, Bremen, Germany) were used for peptide
identification with the following parameters: taxonomy, all entries;
Variable modification, methionine oxidation; fixed modification,
carbamidomethyl (C), Enzyme, trypsin; peptide tolerance,
610 ppm; MS/MS tolerance, 6 0.3 Da; maximum missed
cleavages, 1; Human and murine samples were searched against
species-specific SwissProt databases.
Degradation Assays
Endolysosomal degradation assays were performed with 0.25 mg
ml
21 of substrates (Bet v 1.0101, Bet v 1.0401, RNase A, RNase S,
holo-HRP, apo-HRP) and 0.4 mg ml
21 of isolated microsomal
proteins in a final volume of 20 ml containing 100 mmol L
21
citrate buffer pH 4.8 and 2 mmol L
21 dithiothreitol. Reactions
were conducted for 0, 0.5, 1, 3, 5, 12, 24, 36, and 48 h at 37uC
and stopped by boiling for 5 min at 95uC followed by freezing at
Protein Immunogenicity
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5610
24 U ml
21 of purified human Cathepsin S purchased from
Sigma-Aldrich, St. Louis, MO. Assays were quantitatively
evaluated by flatbed scanner densitometry of GelCodeH Blue
Reagent (Thermo Scientific, Waltham, MA) stained sodium
dodecyl sulfate polyacrylamide gels [23]. Qualitative analysis was
performed by mass spectrometry using an ESI-QTOF mass
spectrometer fitted with a capillary reversed phase HPLC (Waters,
Milford, MA) as described elsewhere [22].
Results
Human and Murine DC-Derived Microsomes Display
Comparable Endolysosomal Degradomes
To conduct endolysosomal in vitro degradation assays we isolated
total microsomal (endolysosomal) fractions from human mDCs,
murine BMDCs, and the murine JAWS II DC line employing a
differential centrifugation protocol. Endolysosomal total proteomes
were analyzed by mass spectrometry-based fingerprinting. 600
different proteins were detected in the microsomal fractions of all
three different DC samples. Proteins belonging to the endolysoso-
mal degradome or that have been shown to be involved in antigen
processing are listed in Table 1. Cathepsins A, B, C, D, L, S, and Z
as well as lysosomal prolylcarboxypeptidase and tripeptidyl
peptidase 1 could be identified in all microsomal fractions. By
contrast, cathepsin K, lysosomal dipeptidyl peptidase 2, and
asparagine endopeptidase (AEP) were not detectable in BMDCs,
and cathepsin H was not measured in the DC line. In summary,
JAWS II DCs contain all important lysosomal endo- and
exopeptidases that have been shown to be involved in antigen
processing [24,25]. Besides proteases, endolysosomal fractions also
contained a multitude of other molecules (non-proteolytic acidic
Table 1. Mass spectrometry based fingerprinting of DC-derived endolysosomal fractions.
Protein mDC BMDC JAWS II SwissProt accession
pep. % pep % pep % human murine
Endoproteases
Cathepsin D 20 60.44 16 59.76 20 63.17 P07339 P18242
C a t h e p s i n K ----6 41.03 - P55097
Cathepsin L 4 29.73 7 42.81 2 15.87 P07711 P06797
Cathepsin S 13 48.94 9 54.12 10 47.94 P25774 O70370
AEP (legumain) - - 4 23.45 2 10.11 - O89017
Endo- and Exoproteases
Cathepsin B 21 54.57 17 55.16 12 47.79 P07858 P10605
Cathepsin H 7 35.22 6 27.93 - - P09668 P49935
Exoproteases
Cathepsin A 7 24.38 16 36.50 15 41.98 P10619 P16675
Cathepsin C 13 41.25 10 29.22 11 32.47 P53634 P97821
Cathepsin Z 9 41.25 12 50.33 13 49.67 Q9UBR2 Q9WUU7
Dipeptidyl peptidase 2 - - 2 6.32 3 9.88 - Q9ET22
Prolylcarboxypeptidase 6 16.73 4 21.59 3 10.59 P42785 Q7TMR0
Tripeptidyl peptidase 1 7 25.93 6 23.31 5 23.21 O14773 O89023
Non-proteolytic acidic hydrolases
Acid lipase 11 37.84 6 21.66 7 29.22 P38571 Q9Z0M5
Acid phosphatase 3 7.8 4 12.77 4 13.71 P11117 P24638
Alpha glucosidase 13 25.32 6 11.54 7 13.85 P10253 P70699
Alpha mannosidase 20 27.1 24 34.85 2 3.16 O00754 O09159
Endolysosomal membrane-associated proteins
Clathrin 54 49.91 59 55.34 46 46.93 Q00610 Q68FD5
LAMP 1 4 9.59 7 17.98 5 14.53 P11279 P11438
LAMP 2 5 11.22 4 9.4 3 7.95 P13473 P17047
LMP 2 3 10.46 3 12.97 4 16.74 Q14108 O35114
VAMP 7 3 26.82 2 18.64 - - P51809 P70280
GTPases involved in vesicular trafficking
ARF 6 6 49.14 5 44.57 - - P62330 P62331
Rab 5a 3 20.93 3 16.28 4 27.44 P20339 Q9CQD1
Rab 5c 9 66.20 9 67.13 7 61.11 P51148 P35278
Rab 7a 14 57.97 13 72.46 11 64.73 P51149 P51150
%, percentage to which identified peptides cover the full length protein sequence; AEP, Asparagine endopeptidase; ARF, ADP-ribosylation factor; LAMP, Lysosome-
associated membrane glycoprotein; LMP, lysosome membrane protein; pep., identified peptides; Rab, Ras-like protein; VAMP, Vesicle-associated membrane protein.
doi:10.1371/journal.pone.0017278.t001
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in vesicular trafficking) that are associated with endosomal and
lysosomal compartments of APCs (Table 1).
Kinetics of Endolysosomal Degradation Differ Between
Structural Variants of the Same Antigen
We compared the kinetics of endolysosomal decomposition for
three pairs of antigens, i.e. structural variants of horseradish
peroxidase (HRP), ribonuclease (RNase), and the major birch pollen
allergen Bet v 1. The comparison of the average half lives (given in
parenthesis) during endolysosomal in vitro degradation revealed that
Bet v 1.0401 (3.8 h), RNase A (.48 h), and holo-HRP (1.5 h) were
more resistant to proteolysis than Bet v 1.0101 (2 h), RNase S (2.2 h),
and apo-HRP (0.4 h), respectively (Figures 1A and 1B). Thus, the
decomposition of Bet v 1.0401 was around two-fold slower than
observed for Bet v 1.0101. For the holo/apo-HRP and RNase A/S
pairs endolysosomal half-life ratios were 3.8 and .20, respectively.
Structural Variants of the Same Antigen Show Similar
Patterns of Proteolytic Fragments
Mass spectrometry-based analysis showed that peptides generat-
ed by endolysosomal in vitro proteolysis formed nested clusters
sharing a common central core but displaying variable flanking
regions. These features are characteristic for MHC (major
histocompatibility complex) class II-bound peptides [22,26].
Notably, peptides derived from both Bet v 1.0101 and Bet v
1.0401 were of 5 to 30 amino acids in length and clustered into 13
different regions along the Bet v 1 sequence. However, central
(region Bet v 121–65 and Bet v 183–115) and C-terminal (region Bet v
1130–159) peptide clusters of the more stable isoallergen Bet v 1.0401
appeared temporally delayed. Interestingly, amino acids differing
between the two Bet v 1 isoforms were rather located apart from
proteolytic cutting sites in central regions of the peptide clusters
(Figures2Aand2B).Proteolyticfragmentsfrombothholo-andapo-
HRP clustered in 5 analogous regions of the full-length molecules.
Due to its highresistanceto endolysosomal hydrolases, we could not
detect any peptides from RNase A, whereas proteolytic fragments
from RNase S were found in 5 different regions (Figure 3).
According to our observations, differences in proteolytic resistance
between pairs of antigens with similar sequence and conserved fold
do not translate into altered patterns of proteolytic fragments.
Endolysosomal Degradation of Bet v 1 is Mediated by
Cathepsin S
Strikingly, the majority of in vitro generated Bet v 1-derived
peptide clusters (Figure 2) was flanked by lysine residues (K20, 54,
Figure 1. Kinetics of endolysosomal proteolysis. 2.5 mg of protein samples were analyzed by SDS-PAGE and GelCodeH Blue staining after 0, 0.5,
1, 3, 5, 12, 24, 36 and 48 h of in vitro degradation using endolysosomal fractions isolated from human mDCs, murine BMDCs, and the DC line JAWS II
(A). For each protein, the half-life during endolysosomal proteolysis was calculated from scanned and densitometrically quantified protein bands (B).
doi:10.1371/journal.pone.0017278.g001
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cathepsin S, a lysosomal cysteine endoprotease favoring substrates
with glutamines or lysines at the P1 position [27], could be involved in
Bet v 1 decomposition. To pursue this idea, we performed in vitro
degradation assays of Bet v 1.0101 with purified cathepsin S, and
identified 31 cathepsin S sites. As shown in Figure 4, cathepsin S sites
seem to be progressively accessible by the protease in a time-
dependent manner. Notably, 8 out of the 13 Bet v 1.0101 peptide
clusters that appeared during endolysosomal proteolysis applying
microsomal fractions could also be generated by cathepsin S alone
(Figure 4). Initially occurring Bet v 1.0101 peptide clusters contained
(cl1–22) or were flanked (cl146–59) by early-cleaved cathepsin S sites
(Figure 4). Short-time degradation assays with human microsomes
(data not shown) revealed that the N-terminal cluster cl1–22 appeared
already after a few minutes of reaction. Thus, cathepsin S might be
engaged in the initial steps of Bet v 1.0101 processing. Late-appearing
peptide clusters,which corresponded to the middle region of the Bet v
1 sequence (cl83–115,c l 83–103,a n dc l 83–97), might be produced by
cathepsin S and AEP,a cysteine endopeptidase that strictlycleaves on
the C-terminal site of asparagine residues (e.g. Bet v 1.0101 N82)
[24,25].
Discussion
The ability to efficiently induce an immune response is a most
important quality of any protein vaccine. As no in vitro tools have
been available so far, immunogenicity is usually assessed in vivo by
animal experiments or by ex vivo cell-based systems. The
immunogenicity of an antigen strongly depends on the character
of its interaction with DCs. These specialized APCs constitute the
interface between antigens and adaptive immunity. After inter-
nalization, DCs convert antigen into peptides that are bound to
Figure 2. Chronology of Bet v 1 peptide cluster formation during endolysosomal proteolysis. Peptides sequenced by mass spectrometry
after 0.5, 1, 3, 5, 12, 24, 36, and 48 h of in vitro digestion with microsomal fractions from mDCs (blue), BMDCs (green) and JAWS II DCs (brown) are
shown for Bet v 1.0101 (A) and Bet v 1.0401 (B), respectively. Regions of predominant peptide clusters (clx-x) are highlighted as bars colored in
different shades of grey depending on their temporal occurrence (average appearance of early clusters: #1 h, intermediate clusters: .1 h and ,5h ,
and late clusters: $5 h. Bet v 1 secondary structures (a-helices and b-sheets) are indicated as framed boxes. Amino acids (n=7) that differ between
the 2 Bet v 1 isoforms are highlighted in orange.
doi:10.1371/journal.pone.0017278.g002
Protein Immunogenicity
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presented to CD4
+ T helper cells. Of note, there is evidence that
various subsets of DCs differ by their capacities of antigen
processing in vivo [28]. For instance, the CD8
+ DEC205
+ subset of
murine splenic DC is more biased for cross-presentation on MHC
class I molecules, whereas the CD8
2 DCIR2
+ DC subset is
Figure 3. Regions of peptide clusters generated by endolysosomal proteolysis. Peptides sequenced by mass spectrometry after 0.5, 1, 3, 5,
12, 24, 36, and 48 h of in vitro digestion with microsomal fractions from mDCs (blue), BMDCs (green) and JAWS II DCs (brown) clustered in distinct
regions along the protein sequence of RNase (A) and peroxidase (B) model antigens. Secondary structures (a-helices and b-sheets) are indicated as
framed boxes.
doi:10.1371/journal.pone.0017278.g003
Figure 4. Cathepsin S digest of Bet v 1. Cathepsin S cleavage sites are depicted in the bar diagram showing their location in the Bet v 1.0101
sequence (x-axis) and the number of different peptides generated per cleavage site (y-axis). According to their temporal accessibility, cathepsin S sites
are highlighted in red (early), orange (intermediate), and yellow (late) in the bar diagram. Generated peptides are shown as purple lines. Bet v 1.0101
secondary structures (a-helices and b-sheets) are indicated as framed boxes. Regions of Bet v 1.0101 peptide clusters (clx-x) generated by
endolysosomal proteases isolated from DCs are depicted as grey boxes.
doi:10.1371/journal.pone.0017278.g004
Protein Immunogenicity
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increased expression of proteins involved in the exogenous antigen
processing pathway, including cathepsins C, H, Z, and AEP.
Further, it has been shown that compared to monocyte-derived
DCs, conventional DCs are much more efficient in antigen
processing and presentation independent from the route of antigen
uptake [29].
Within the course of antigen processing, several steps (antigen
uptake, DC activation, peptide generation, MHC-peptide complex
stability and density) can be decisive regarding the immunogenic-
ity of a given antigen. For instance, the internalization of
ovalbumin conjugated to trimethyl chitosan by DCs was 5-fold
increased leading to a 1,000-fold higher ovalbumin-specific IgG
titers in immunized mice [30]. Apart from such adjuvant-
dependent aspects, also properties intrinsic to the antigen
(posttranslational modifications, structural features, and stability)
can influence immunogenicity. For example, targeting receptor-
mediated endocytosis, mannosylated ovalbumin induced a much
stronger proliferation of ovalbumin-specific T cells than its
unglycosylated counterpart [31]. Moreover, although structural
discrepancies between isoforms of the birch pollen major allergen
are minor (PDB accession numbers are given in parenthesis),
uptake and endocytosis of Bet v 1.0101 (PDB: 1BV1) by murine
BMDCs were significantly slower and less efficient than observed
for Bet v 1.0401 (PDB: 3K78). The two isoforms also induced
divergent patterns of DC activation and humoral responses, which
have been attributed to cysteine-mediated dimerization due to a
serine to cysteine exchange in Bet v 1.0401 [8]. In more detail,
mice immunized with Bet v 1.0401 displayed a comparable IgE
but a strongly elevated IgG and IgA response. On DCs Bet v
1.0401 elicited a significantly increased expression of CD80 and
CD86 activation markers, whereas the secretion of cytokines
antagonizing DC maturation and activation (IL-6) was enhanced
in BMDCs stimulated with Bet v 1.0101. Notably, insufficient DC
activation might be generally responsible for a shift towards the
allergic immune response [32] and could in part explain
hypoallergenicity of Bet v 1.0401.
Antigen uptake and DC activation might also affect the
generation of T cell stimulatory peptides, a complex process that
involves the sequential action of acidic hydrolases in endosomal
and lysosomal compartments of the DC [24,33]. Antigens that are
rather stable to endolysosomal proteolysis can persistently provide
peptides for binding to MHC molecules, thus ensuring efficient
presentation to T cells and thus, high immunogenicity. By
contrast, instable molecules fail to elicit an immune response due
to rapid T cell epitope destruction [15,16]. Hence, efficient
antigen uptake of rather stable antigens might facilitate continuous
delivery of peptides that can properly bind the MHC class II
grove, thereby favoring a high density of MHC-peptide complexes
on the surface of the DC for T cell presentation. Notably, the
density of T cell epitopes is crucial for T cell activation [34] and
could even be decisive in the development of a Th1 or allergic Th2
biased response [35]. Apart from such quantitative aspects, also
the quality of peptides generated by endolysosomal proteases has a
strong impact on the immunogenicity of proteins. For example,
stabilization of MHC-peptide complexes by substituting single
amino acids in a tumor antigen-derived T cell epitope increased
specific T cell responses up to 50-fold [36]. Hence, the 7 amino
acid exchanges in the Bet v 1.0401 isoform might also contribute
to its stronger immunogenicity.
In the present study, we exploited the link between resistance to
endolysosomal proteolysis and immunogenicity to establish a high-
throughput screening procedure for rational protein vaccine
development. Although the capacity of an antigen to induce an
immune response depends on many parameters, according to our
data susceptibility to endolysosomal proteases seems to be a key
factor determining immunogenicity. Nevertheless, as cell-free
endolysosomal in vitro degradations do not encompass important
parameters of immunogenicity like antigen uptake, DC activation,
and stability of the MHC-peptide complex, it cannot reflect the
complex situation of antigen processing in vivo. Therefore, this
method cannot be used for T cell epitope determination, and
assessments on protein immunogenicity might deviate in some
cases from in vivo obtained data. Still, the assay described here
represents an excellent tool requiring only standard laboratory
equipment, a tissue homogenizer, an ultracentrifuge, and a cell
culture facility for rapid and simple assessment of protein
immunogenicity. Because costs, time, up-scalability, and standard-
ization problems limit the use of human as well as animal-derived
DCs, we introduced the murine commercially available DC cell
line JAWS II as source for endolysosomal proteases. Comparative
mass spectrometry-based analysis of the protein composition
provided strong evidence of the similarity between the different
degradomes. To our knowledge, this represents the first study on
the endolysosomal proteome from mice and men. We found that
the proteome data nicely correlated with degradative activity and
proteolytic specificity of the degradome using RNase A, HRP, and
Bet v 1.0101 model antigens as substrates. Because structural
features of proteins seem to be intimately connected to their
immunogenic activity, as demonstrated earlier for structural
variants of RNase A, HRP [15,16], and Bet v 1 [8], we analyzed
the kinetics and degradation patterns of RNase S, apo-HRP and
Bet v 1.0401. Indeed, we observed remarkable differences in the
proteolytic resistance and kinetics of degradation among the
investigated antigens. It has been demonstrated that local
structural flexibility is a general requirement for proteolytic
sensitivity and that deletion of such elements enhances protein
stability [37]. However, we did not observe a strict correlation
between proteolytic cutting sites and loop structure elements in our
model antigens and variants thereof. Of note, the flexible C-
terminal loop of Bet v 1 (Bet v 1123–129) seems to be heavily
degraded by lysosomal proteases, as we could not detect any in vitro
generated peptides corresponding to this region. Thus, deletion of
Bet v 1123–129 might increase Bet v 1.0101 stability and
immunogenicity. Another possibility would be the targeting of
frequently used and surface-exposed cathepsin S cleavage sites of
Bet v 1.0101 (F19-K20, K65-Y66, G92-D93, K115-I116, and
K134-A135) identified here.
Other factors influencing proteolytic sensitivity and immuno-
genicity are aggregation [8], integrity of the polypeptide backbone,
and the presence of ligands [15,16]. As described above, due to a
serine to cysteine exchange at position 112, Bet v 1.0401 shows a
high tendency to form disulfide-linked aggregates [8]. Presumably
due to steric hindrance of proteolytic cutting sites, this isoform
appears twice as stable in endolysosomal in vitro degradation assays
than Bet v 1.0101. Accordingly, antibody and T cell responses are
elevated in mice immunized with Bet v 1.0401. Similarly, RNase
A induces more than 10,000-fold stronger T cell and IgG
responses than RNase S, which is destabilized by a single
subtilisin-mediated peptide bond cleavage between A20 and
S21. During endolysosomal in vitro proteolysis RNase S was
degraded more than 20-fold faster than RNase A. Moreover, apo-
HRP lacking Ca
2+ ions and the prosthetic heme group is a weak
immunogen and displayed about 4-fold stronger sensitivity to
endolysosomal proteases during in vitro degradation than fully
equipped holo-HRP [15,16].
In summary, our data convincingly showed that not only the
proteome fingerprint but also the proteolytic activity in terms of
Protein Immunogenicity
PLoS ONE | www.plosone.org 7 February 2011 | Volume 6 | Issue 2 | e17278specificity and kinetics of the analyzed degradomes is equivalent.
Our findings are further supported by degradation experiments of
Bet v 1.0101 using purified cathepsin S, an important endolyso-
somal protease. Remarkably, the patterns obtained by degradation
with cathepsin S alone resembled those observed in reactions
applying endolysosomal fractions. Despite the advantage of
straightforward determination of proteolytic epitopes, the single
protease approach cannot reliably mimic the complexity of a
whole degradome since concerted action of proteases might be
crucial in the kinetics of antigen degradation. As kinetics is the key
indicator for assaying immunogenicity, this strategy would lack
general applicability.
To conclude, the adoption of the JAWS II DC line for
endolysosomal in vitro degradation facilitated the development of a
simple, rapid, reliable, and easily upscalable comparative assay to
select highly immunogenic allergy vaccine candidates from a pool
of related molecules for pre-clinical evaluation. Data can be
obtained within one week, and RNases A and S might serve as
internal references. The method described here is very useful to
study the immunogenic properties of a protein, and can help to
replace, reduce, and refine animal experiments in allergy research
and vaccine development in general.
Author Contributions
Conceived and designed the experiments: ME MW FF. Performed the
experiments: ME AJ PB SR SH UP CK. Analyzed the data: ME AJ PB.
Contributed reagents/materials/analysis tools: BB CGH FF. Wrote the
paper: ME MW FF.
References
1. Rolland JM, Gardner LM, O’Hehir RE (2009) Allergen-related approaches to
immunotherapy. Pharmacol Ther 121: 273–284.
2. Egger M, Hauser M, Himly M, Wopfner N, Wallner M, et al. (2009)
Development of recombinant allergens for diagnosis and therapy. Front Biosci
(Elite Ed) 1: 77–90.
3. Valenta R, Ferreira F, Focke-Tejkl M, Linhart B, Niederberger V, et al. (2010)
From allergen genes to allergy vaccines. Annu Rev Immunol 28: 211–241.
4. Ferreira F, Hirtenlehner K, Jilek A, Godnik-Cvar J, Breiteneder H, et al. (1996)
Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the
major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for
immunotherapy. J Exp Med 183: 599–609.
5. Linhart B, Jahn-Schmid B, Verdino P, Keller W, Ebner C, et al. (2002)
Combination vaccines for the treatment of grass pollen allergy consisting of
genetically engineered hybrid molecules with increased immunogenicity. Faseb J
16: 1301–1303.
6. Saarelainen S, Zeiler T, Rautiainen J, Narvanen A, Rytkonen-Nissinen M, et al.
(2002) Lipocalin allergen Bos d 2 is a weak immunogen. Int Immunol 14:
401–409.
7. Scheiblhofer S, Stoecklinger A, Gruber C, Hauser-Kronberger C, Alinger B,
et al. (2007) Gene gun immunization with clinically relevant allergens aggravates
allergen induced pathology and is contraindicated for allergen immunotherapy.
Mol Immunol 44: 1879–1887.
8. Zaborsky N, Brunner M, Wallner M, Himly M, Karl T, et al. (2010) Antigen
aggregation decides the fate of the allergic immune response. J Immunol 184:
725–735.
9. Smole U, Balazs N, Hoffmann-Sommergruber K, Radauer C, Hafner C, et al.
(2010) Differential T-cell responses and allergen uptake after exposure of
dendritic cells to the birch pollen allergens Betv1.0101, Betv1.0401 and
Betv1.1001. Immunobiology.
10. Wagner S, Radauer C, Bublin M, Hoffmann-Sommergruber K, Kopp T, et al.
(2008) Naturally occurring hypoallergenic Bet v 1 isoforms fail to induce IgE
responses in individuals with birch pollen allergy. J Allergy Clin Immunol 121:
246–252.
11. Mutschlechner S, Deifl S, Bohle B (2009) Genetic allergen modification in the
development of novel approaches to specific immunotherapy. Clin Exp Allergy
39: 1635–1642.
12. Wallner M, Briza P, Thalhamer J, Ferreira F (2007) Specific immunotherapy in
pollen allergy. Curr Opin Mol Ther 9: 160–167.
13. Wallner M, Himly M, Neubauer A, Erler A, Hauser M, et al. (2009) The
influence of recombinant production on the immunologic behavior of birch
pollen isoallergens. PLoS One 4: e8457.
14. Carra JH, Welcher BC, Schokman RD, David CS, Bavari S (2003) Mutational
effects on protein folding stability and antigenicity: the case of streptococcal
pyrogenic exotoxin A. Clin Immunol 108: 60–68.
15. Delamarre L, Couture R, Mellman I, Trombetta ES (2006) Enhancing
immunogenicity by limiting susceptibility to lysosomal proteolysis. J Exp Med
203: 2049–2055.
16. Delamarre L, Pack M, Chang H, Mellman I, Trombetta ES (2005) Differential
lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science
307: 1630–1634.
17. Vidard L, Rock KL, Benacerraf B (1992) Diversity in MHC class II ovalbumin
T cell epitopes generated by distinct proteases. J Immunol 149: 498–504.
18. Thalhamer T, Dobias H, Stepanoska T, Proll M, Stutz H, et al. (2010)
Designing hypoallergenic derivatives for allergy treatment by means of in silico
mutation and screening. J Allergy Clin Immunol 125: 926–934 e910.
19. Wallner M, Stocklinger A, Thalhamer T, Bohle B, Vogel L, et al. (2007) Allergy
multivaccines created by DNA shuffling of tree pollen allergens. J Allergy Clin
Immunol 120: 374–380.
20. Ferreira FD, Hoffmann-Sommergruber K, Breiteneder H, Pettenburger K,
Ebner C, et al. (1993) Purification and characterization of recombinant Bet v I,
the major birch pollen allergen. Immunological equivalence to natural
Bet v I. J Biol Chem 268: 19574–19580.
21. Jiang X, Shen C, Rey-Ladino J, Yu H, Brunham RC (2008) Characterization of
murine dendritic cell line JAWS II and primary bone marrow-derived dendritic
cells in Chlamydia muridarum antigen presentation and induction of protective
immunity. Infect Immun 76: 2392–2401.
22. Mutschlechner S, Egger M, Briza P, Wallner M, Lackner P, et al. (2010)
Naturally processed T cell-activating peptides of the major birch pollen allergen.
J Allergy Clin Immunol 125: 711–718, 718 e711-718 e712.
23. Tan HY, Ng TW, Liew OW (2007) Effects of light spectrum in flatbed scanner
densitometry of stained polyacrylamide gels. Biotechniques 42: 474–478.
24. Colbert JD, Matthews SP, Miller G, Watts C (2009) Diverse regulatory roles for
lysosomal proteases in the immune response. Eur J Immunol 39: 2955–2965.
25. Matthews SP, Werber I, Deussing J, Peters C, Reinheckel T, et al. (2010)
Distinct protease requirements for antigen presentation in vitro and in vivo.
J Immunol 184: 2423–2431.
26. Lippolis JD, White FM, Marto JA, Luckey CJ, Bullock TN, et al. (2002) Analysis
of MHC class II antigen processing by quantitation of peptides that constitute
nested sets. J Immunol 169: 5089–5097.
27. Lutzner N, Kalbacher H (2008) Quantifying cathepsin S activity in antigen
presenting cells using a novel specific substrate. J Biol Chem 283: 36185–36194.
28. Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C,
et al. (2007) Differential antigen processing by dendritic cell subsets in vivo.
Science 315: 107–111.
29. Kamphorst AO, Guermonprez P, Dudziak D, Nussenzweig MC (2010) Route of
antigen uptake differentially impacts presentation by dendritic cells and activated
monocytes. J Immunol 185: 3426–3435.
30. Slutter B, Soema PC, Ding Z, Verheul R, Hennink W, et al. Conjugation of
ovalbumin to trimethyl chitosan improves immunogenicity of the antigen.
J Control Release 143: 207–214.
31. Lam JS, Mansour MK, Specht CA, Levitz SM (2005) A model vaccine
exploiting fungal mannosylation to increase antigen immunogenicity. J Immunol
175: 7496–7503.
32. Paul WE, Zhu J.How are T(H)2-type immune responses initiated and amplified?
Nat Rev Immunol 10: 225–235.
33. Honey K, Rudensky AY (2003) Lysosomal cysteine proteases regulate antigen
presentation. Nat Rev Immunol 3: 472–482.
34. Gonzalez PA, Carreno LJ, Coombs D, Mora JE, Palmieri E, et al. (2005) T cell
receptor binding kinetics required for T cell activation depend on the density of
cognate ligand on the antigen-presenting cell. Proc Natl Acad Sci U S A 102:
4824–4829.
35. Buatois V, Baillet M, Becart S, Mooney N, Leserman L, et al. (2003) MHC class
II-peptide complexes in dendritic cell lipid microdomains initiate the CD4 Th1
phenotype. J Immunol 171: 5812–5819.
36. Baratin M, Kayibanda M, Ziol M, Romieu R, Briand JP, et al. (2002) Amino
acid modifications in the wild type sequence p53 232-240 overcome the poor
immunogenicity of this self tumour epitope. J Pept Sci 8: 327–334.
37. Carmicle S, Steede NK, Landry SJ (2007) Antigen three-dimensional structure
guides the processing and presentation of helper T-cell epitopes. Mol Immunol
44: 1159–1168.
Protein Immunogenicity
PLoS ONE | www.plosone.org 8 February 2011 | Volume 6 | Issue 2 | e17278